SCHEMBL8200742

SCHEMBL8200742

Cc1cc(CNC(=O)OC(C)(C)C)cc2c1OCC(=O)N2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.50
BRD4 O60885 1/20 0.43
CREBBP Q92793 1/20 0.43
TP53 P04637 2/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ADRB2 P07550 9/20 0.39
ADRB1 P08588 9/20 0.39
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
ADRA1A P35348 1/20 0.38
PTGS2 P35354 1/20 0.38
HTR2B P41595 1/20 0.38
SLC6A3 Q01959 1/20 0.38
PDE4D Q08499 1/20 0.38
KCNH2 Q12809 1/20 0.38
PARP1 P09874 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8195296 0.88 BRD4 (0.43) NR3C2BRD4CREBBPL3MBTL1ADRB2
SCHEMBL8196796 0.88 NR3C2 (0.47) NR3C2TP53LMNAADRB2ADRB1
SCHEMBL7276275 0.81 PARP1 (0.56) NR3C2BRD4CREBBPPARP1MAPT
SCHEMBL8197296 0.79 BRD4 (0.39) NR3C2BRD4CREBBPL3MBTL1ADRB2
SCHEMBL8192361 0.79 TSHR (0.51) BRD4CREBBPTP53LMNAL3MBTL1
SCHEMBL8196981 0.78 PARP1 (0.40) NR3C2BRD4CREBBPL3MBTL1PARP1
SCHEMBL13343850 0.76 BRD4 (0.54) NR3C2BRD4CREBBPTP53LMNA
SCHEMBL14079839 0.76 ADRB2 (0.39) NR3C2ADRB2ADRB1CHRM2HTR1A
SCHEMBL4145619 0.75 KDM4A (0.47) BRD4LMNAL3MBTL1
SCHEMBL8202568 0.73 RPS6KA1 (0.39) BRD4CREBBPL3MBTL1ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 NR3C2 2202/4885BRD4 338/4885CREBBP 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.